Neurogene Inc (NGNE)
Healthcare
Biotechnology
—
32.90 $
-2.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Neurogene Inc (NGNE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -26 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.3 | -12 | -30 | -22 | -16 | -16 | -17 | -21 | -19 | -20 | -17 | -26 | -82 | |
| 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.9 | 3.2 | |
| 0.4 | 0.4 | 0.4 | 1.0 | 2.3 | 2.5 | 2.5 | 4.0 | 3.4 | 3.4 | 3.4 | 3.6 | 14 | |
| 1.2 | 1.6 | 1.3 | -6.7 | -1.1 | 2.6 | -0.9 | -1.4 | -0.4 | -1.3 | 3.4 | 1.2 | 2.9 | |
| 0.1 | 0.1 | 0.2 | 0.1 | 0.5 | 0.2 | 0.1 | 0.8 | 0.1 | 0.1 | 0.1 | 0.3 | 0.7 | |
| -0.1 | -0.1 | 17 | 30 | -24 | -29 | -103 | -45 | 7.5 | 22 | 30 | 46 | 106 | |
| – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| -0.1 | -1.8 | 92 | -6.5 | 0.4 | 0.1 | 190 | 0.0 | 0.1 | 9.9 | 21 | 0.2 | 31 | |
| -9.5 | -13 | 123 | 1.8 | -39 | -44 | 70 | -66 | -12 | 12 | 33 | 20 | 53 | |
| -9.4 | -12 | -29 | -22 | -16 | -16 | -18 | -22 | -20 | -20 | -17 | -26 | -83 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.